The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

The majority of South African HIV patients could be switched to the World Health Organization’s recommended first-line regimen if the country adopts advice from leading doctors. This would allow most ...

The British HIV Association (BHIVA) has recommended that everyone living with HIV aged 40 and over should take a statin to reduce their risk of heart disease, even if they do not have raised ...

Despite the incredible efficacy of oral pre-exposure prophylaxis (PrEP) and 78 countries currently offering PrEP in some form, its effectiveness at reducing HIV incidence in the real world has been ...

A woman in New York City has no detectable HIV 14 months after stopping antiretroviral therapy following a transplant of HIV-resistant stem cells, according to a presentation yesterday at the ...

Over half of funding for anti-gender actors in Europe appears to come from within Europe itself, with significant amounts of money also flowing from the US and the Russian Federation, according to ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

Doxycycline post-exposure prophylaxis (doxyPEP), which was found to be highly effective at preventing sexually transmitted infections (STIs) among gay men and transgender women, did not protect young ...

Advocates from around the world came together at the U=U Global Summit at the 24th International AIDS Conference (AIDS 2022) in Montreal last month to share successes and challenges that continue to ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

While there is a path to injectable PrEP becoming available in the next five years, the widespread use of injectables to treat people living with HIV in low- and middle-income countries is unlikely in ...